Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

McKinsey
Moodys
Boehringer Ingelheim
Colorcon
Express Scripts
AstraZeneca

Last Updated: November 13, 2019

DrugPatentWatch Database Preview

Enasidenib mesylate - Generic Drug Details

See Plans and Pricing

« Back to Dashboard

What are the generic drug sources for enasidenib mesylate and what is the scope of patent protection?

Enasidenib mesylate is the generic ingredient in one branded drug marketed by Celgene Corp and is included in one NDA. There are five patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Enasidenib mesylate has seventy-two patent family members in thirty-four countries.

One supplier is listed for this compound.

Summary for enasidenib mesylate
International Patents:72
US Patents:5
Tradenames:1
Applicants:1
NDAs:1
Suppliers / Packagers: 1
Bulk Api Vendors: 47
Clinical Trials: 2
Patent Applications: 47
DailyMed Link:enasidenib mesylate at DailyMed
Recent Clinical Trials for enasidenib mesylate

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Jonsson Comprehensive Cancer CenterPhase 2
M.D. Anderson Cancer CenterPhase 2
National Cancer Institute (NCI)Phase 2

See all enasidenib mesylate clinical trials

Pharmacology for enasidenib mesylate
Synonyms for enasidenib mesylate
1446502-11-9
1650550-25-6
2-methyl-1-((4-(6-(trifluoromethyl)pyridin-2-yl)-6-((2-(trifluoromethyl)pyridin-4-yl)amino)-1,3,5-triazin-2-yl)amino)propan-2-ol
2-Methyl-1-(4-(6-(trifluoromethyl)pyridin-2-yl)-6-(2-(trifluoromethyl)pyridin-4-ylamino)-1,3,5-triazin-2-ylamino)propan-2-ol
2-Methyl-1-[(4-[6-(Trifluoromethyl)pyridin-2-Yl]-6-{[2-(Trifluoromethyl)pyridin-4-Yl]amino}-1,3,5-Triazin-2-Yl)amino]propan-2-Ol
2-methyl-1-[[4-[6-(trifluoromethyl)pyridin-2-yl]-6-[[2-(trifluoromethyl)pyridin-4-yl]amino]-1,3,5-triazin-2-yl]amino]propan-2-ol
2-Propanol, 2-methyl-1-((4-(6-(trifluoromethyl)-2-pyridinyl)-6-((2-(trifluoromethyl)-4-pyridinyl)amino)-1,3,5-triazin-2-yl)amino)-
2-Propanol, 2-methyl-1-((4-(6-(trifluoromethyl)-2-pyridinyl)-6-((2-(trifluoromethyl)-4-pyridinyl)amino)-1,3,5-triazin-2-yl)amino)-, methanesulfonate (1:1)
3T1SS4E7AG
69Q
AG 221
AG-221
AG-221 (Enasidenib)
AG-221 mesylate
AG-221; Enasidenib
AG-221(Enasidenib)
AG221
AKOS026750439
BCP16041
BCP26166
CC 90007
CC-90007
CC-90007 Free Base
CC90007
CHEMBL3989908
CHEMBL3989931
CS-5017
CS-7541
D10901
D11044
DB13874
Enasidenib
Enasidenib (mesylate)
Enasidenib (USAN/INN)
Enasidenib [INN]
Enasidenib [USAN:INN]
Enasidenib mesilate
Enasidenib mesylate (USAN)
Enasidenib mesylate [USAN]
Enasidenib mesylate; AG-221 mesylate
Enasidenib methanesulfonate
EX-A1972
EX-A654
FT-0700204
GTPL8960
HY-18690
HY-18690A
IDHIFA
Idhifa (TN)
J-690181
KB-3356927
KS-000006AW
NCGC00479249-03
NCGC00479249-05
s8205
SB19193
SCHEMBL15102202
SCHEMBL16448052
UF6PC17XAV
UNII-3T1SS4E7AG
UNII-UF6PC17XAV
ZINC222731806

US Patents and Regulatory Information for enasidenib mesylate

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Celgene Corp IDHIFA enasidenib mesylate TABLET;ORAL 209606-002 Aug 1, 2017 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
Celgene Corp IDHIFA enasidenib mesylate TABLET;ORAL 209606-002 Aug 1, 2017 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
Celgene Corp IDHIFA enasidenib mesylate TABLET;ORAL 209606-002 Aug 1, 2017 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
Celgene Corp IDHIFA enasidenib mesylate TABLET;ORAL 209606-002 Aug 1, 2017 RX Yes Yes   Start Trial   Start Trial Y Y   Start Trial
Celgene Corp IDHIFA enasidenib mesylate TABLET;ORAL 209606-001 Aug 1, 2017 RX Yes No   Start Trial   Start Trial Y Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
McKinsey
Harvard Business School
Medtronic
Express Scripts
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.